Key Takeaways:
Denali Therapeutics Inc. (NASDAQ: DNLI) said the initial commercial uptake of its first approved drug, AVLAYAH, is exceeding expectations after its March 24 accelerated approval for pediatric Hunter syndrome.
"From an engagement and an interest perspective, I think we're safe to say that we're ahead of expectations," Alexander Schuth, Chief Operating Officer and Chief Financial Officer at Denali Therapeutics, said at a Bank of America Securities conference.
The company has seen strong interest from physicians and generally smooth reimbursement processes, with the first commercial patients—who were not part of clinical trials—already starting therapy. Schuth noted one patient began treatment just three and a half weeks after approval. While Denali is tracking patient start forms, it is not yet disclosing specific numbers.
The positive launch is a critical step for Denali, validating its blood-brain barrier transport technology and opening a significant market. AVLAYAH is designed to treat both the neurologic and whole-body aspects of Hunter syndrome, a key advantage over the current standard of care, ELAPRASE, which generates about $700 million in annual sales and does not cross the blood-brain barrier.
Denali views AVLAYAH and its Sanfilippo syndrome candidate, DNL126, as a combined $1 billion market opportunity, an estimate Schuth called "quite conservative." The company has priced AVLAYAH at a premium to ELAPRASE. The current approval covers pediatric patients, representing about 70% of the Hunter syndrome population. Denali anticipates the label could expand to include adults following data from its Phase 2/3 COMPASS confirmatory study, expected by the end of next year.
Beyond Hunter syndrome, Denali is advancing a broad pipeline. The company believes it has the data to file for approval of DNL126 for Sanfilippo syndrome in 2027. It is also preparing for a clinical study in Pompe disease and has key data readouts expected this year and next for partnered programs in Parkinson’s disease, tau, and frontotemporal dementia.
The successful launch of AVLAYAH is a major transition for Denali, establishing it as a commercial-stage company. Investors will be watching for the first sales figures and data from the COMPASS study to confirm the drug's long-term potential.
This article is for informational purposes only and does not constitute investment advice.
